SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The disclosure confirms Harmonic Inc.'s previously announced Asset Purchase Agreement to sell its Video Business to Leone Media Inc. (MediaKind) for $145 million in cash, with expected closing in Q2 2026. This is a material disposition of a business segment that would significantly affect the registrant's financial position and operations, meeting the definition of M&A activity under Item 1.02 or 2.01.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from ARKO Corp.'s 2026 Annual Meeting held on June 4, 2026. The filing presents final voting tallies for three proposals: election of six directors, advisory approval of named executive officer compensation, and ratification of Grant Thornton LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material disclosure of shareholder meeting outcomes.
View raw filing on EDGAR →Garmin held its annual general meeting on June 5, 2026, with shareholders voting on 14 proposals including approval of financial statements, director elections, executive compensation approvals, and auditor ratification. All matters were approved by shareholders.
View raw filing on EDGAR →Shareholders approved a $4.20 per-share cash dividend to be paid from capital contribution reserves in four quarterly installments, with the first $1.05 installment payable on June 26, 2026. This material capital allocation decision was authorized at the annual meeting.
View raw filing on EDGAR →The filing discloses an amendment to a material revolving credit facility with City National Bank that extends the maturity date to June 8, 2029 (or March 31, 2029 if certain notes are not refinanced). While this is a material definitive agreement under Item 1.01, it does not fit cleanly into the M&A activity category—it is a debt facility amendment rather than an acquisition, disposition, merger, or change of control. The conditional maturity structure tied to refinancing of 8.50% notes due 2029 suggests potential refinancing risk, but the disclosure does not rise to the level of a covenant breach or going-concern warning. This is best classified as other_material because it is a material debt restructuring that affects the company's capital structure and liquidity profile, but lacks the specific hallmarks of the more defined event types.
View raw filing on EDGAR →Kraft Heinz is redeeming $1 billion of its $1.35 billion outstanding 3.875% Senior Notes due 2027, representing approximately 74% of the outstanding principal. While this is a debt management action rather than a traditional material event category, the scale of the redemption (reducing near-term debt maturity by a substantial amount) and the make-whole premium payment would materially affect the company's liquidity and financial position, warranting disclosure to investors.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from AN2 Therapeutics' June 3, 2026 annual meeting, reporting the certified voting outcomes for two proposals: (1) election of three Class I directors (Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D.) and (2) ratification of PricewaterhouseCoopers LLP as independent auditor. The filing directly matches Item 5.07 requirements and provides detailed vote tallies including votes for/against, withheld votes, and broker non-votes. Director elections are material governance events affecting board composition.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Ooma's June 4, 2026 annual meeting, covering three proposals: election of Class II directors (Butenhoff and Mann), ratification of KPMG LLP as independent auditor, and advisory vote on named executive officer compensation. The filing reports final voting tallies for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →The Board of Directors approved the termination of Craig Huffman from his position as Chief Legal Officer effective immediately. This is a clear executive departure—the principal disclosed action is a named officer leaving his role. The termination of a C-suite legal officer is material to investors as it affects the company's governance and compliance leadership structure.
View raw filing on EDGAR →DaVita entered into a Ninth Amendment to its Credit Agreement on June 8, 2026, providing for an incremental $500 million borrowing under its senior secured term loan B facility. This material financing amendment significantly affects the company's capital structure and financial obligations.
View raw filing on EDGAR →DaVita disclosed the final certified results of its June 4, 2026 Annual Meeting of Stockholders, including voting outcomes on the election of nine directors, ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →T1 Energy Inc. disclosed entry into a definitive agreement to acquire KORE Power, Inc., a BESS and software solutions provider, with a purchase enterprise value of approximately $32 million consisting of equity, cash, and debt assumption. The transaction includes $9.6 million in closing consideration paid in common stock and potential earn-outs up to $15.1 million, representing a material acquisition that would affect a reasonable investor's assessment of the company's strategic direction and financial position.
View raw filing on EDGAR →SUNation Energy entered into a securities purchase agreement on June 7, 2026 to sell 2,390,000 unregistered shares of common stock at $1.13 per share for gross proceeds of $2,700,700 to institutional and accredited investors pursuant to Section 4(a)(2) and Rule 506 exemptions. This is a classic private placement of unregistered equity securities, which is material to investors as it dilutes existing shareholders and signals the company's need to raise capital.
View raw filing on EDGAR →Paul Lalljie was appointed to the Board of Directors and the Audit Committee, effective June 5, 2026. The appointment restores NYSE compliance with Section 303A.07(a) regarding audit committee independence requirements. Compensatory arrangements include an annual cash retainer of $150,000 and annual Class A Stock award of $150,000.
View raw filing on EDGAR →A press release was issued on June 8, 2026 and furnished under Item 8.01 (Other Events). The specific substance of the announcement cannot be determined from the available classification data, as the actual content is referenced only as Exhibit 99.1.
View raw filing on EDGAR →SUNation Energy entered into an Agreement and Plan of Merger with Suniva, Inc. on June 5, 2026, whereby Suniva will merge with SUNation's wholly owned subsidiary, with Suniva continuing as a wholly owned subsidiary of SUNation. The transaction represents a material change of control, with pre-Merger Suniva stockholders expected to own approximately 98.2% of the combined company post-closing.
View raw filing on EDGAR →Profusa submitted an Advance Notice on June 8, 2026 to Ascent Partners Fund LLC requesting purchase of common stock under an equity line of credit arrangement. The disclosure describes a dilutive financing mechanism allowing issuance of up to 9.99% of outstanding shares per Advance Notice (capped at $200,000), with pricing based on VWAP and a True-Up Mechanism that could trigger additional share issuance if prices decline. This is a classic equity line of credit (ELOC) arrangement that signals potential dilution and cash-raising activity typical of small-cap issuers under financial pressure.
View raw filing on EDGAR →The filing discloses execution of a business combination agreement between Inflection Point Acquisition Corp. VI and Quantum Space, LLC, involving a merger structure with PubCo and Merger Sub. This constitutes entry into a material acquisition/change of control transaction, the core event type for M&A activity under Item 1.01. The disclosure includes details on the Up-C structure, organizational changes, and concurrent financing arrangements, all hallmarks of a significant business combination.
View raw filing on EDGAR →Tyler Hassen was appointed as a member of the Company's Board of Directors, in addition to his role as Chief Executive Officer. This represents a material governance change affecting board composition.
View raw filing on EDGAR →CleanCore Solutions announced a comprehensive strategic pivot from a cleaning products and digital asset treasury company to an AI critical infrastructure company, including a non-binding letter of intent to acquire majority ownership in a data center project (the Midwest Project) and plans to explore selling its legacy cleaning products business and Dogecoin holdings to redeploy capital into data center and computing infrastructure.
View raw filing on EDGAR →CleanCore Solutions entered into a Controlled Equity Offering Sales Agreement on June 8, 2026, authorizing the sale of up to $750 million in common stock through Cantor Fitzgerald and Curvature Securities. This is a material dilutive issuance under an at-the-market offering structure (Item 1.01), representing a substantial potential equity raise that would significantly dilute existing shareholders. The filing also discloses termination of a prior ATM agreement and payments to prior agents, confirming the capital-raising intent.
View raw filing on EDGAR →This disclosure describes the completion of a SPAC IPO and related private placements, including the exercise of an over-allotment option. While the IPO itself occurred on May 18, 2026 (prior to this 8-K filing), this Item 8.01 confirms the subsequent over-allotment exercise on May 20-21, 2026, and the resulting capital raised ($175.875 million in trust). This is a material capital-raising event for a blank-check company, but it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, or other specific event types). The disclosure is material to investors assessing the company's capitalization and ability to pursue a business combination.
View raw filing on EDGAR →The filing discloses a favorable appellate court decision in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc., where the U.S. Court of Appeals for the Federal Circuit affirmed that Nexus's generic minocycline product infringed two of CorMedix's patents and rejected the invalidity challenge. This is a material litigation outcome that protects the Company's intellectual property and competitive position, warranting disclosure under Item 7.01 as a material event.
View raw filing on EDGAR →Solidion Technology entered into a Securities Purchase Agreement on June 7, 2026, to issue 750,000 shares of common stock and pre-funded warrants to purchase 1,583,000 additional shares in a private placement under Section 4(a)(2) and Rule 506(b) exemptions, raising approximately $32 million in net proceeds. This unregistered equity issuance materially increases share count and dilutes existing shareholders.
View raw filing on EDGAR →Keystone Acquisition Corp. consummated its IPO on June 4, 2026, raising $287.5 million through the issuance of 28.75 million units and entering into multiple definitive agreements (underwriting, warrant, trust, and registration rights agreements) central to the company's formation and capitalization as a special purpose acquisition company.
View raw filing on EDGAR →Keystone completed a private placement of 8,468,750 unregistered warrants to the Sponsor and Representatives for $8.47 million in gross proceeds, simultaneously with the IPO closing on June 4, 2026, with favorable terms including cashless exercise and registration rights.
View raw filing on EDGAR →Three independent directors—Speaker John A. Boehner, Paul Y. Cho, and Martin Payne—were appointed to the Board effective June 2, 2026, in connection with the IPO, with committee assignments and equity compensation of 25,000 to 40,000 Class B ordinary shares each.
View raw filing on EDGAR →Keystone adopted an Amended and Restated Memorandum and Articles of Association in connection with the IPO on June 2, 2026, reflecting governance document changes required for the newly public company.
View raw filing on EDGAR →InterPrivate Investment Partners V completed its initial public offering on June 5, 2026, raising $201.25 million in gross proceeds through the sale of 20.125 million units. The transaction involved entry into multiple material definitive agreements including underwriting, warrant, registration rights, and administrative agreements that govern the company's capital structure and governance.
View raw filing on EDGAR →The company completed a private placement of 540,000 units (365,000 to Sponsor and 175,000 to underwriters) at $10.00 per unit, generating $5.4 million in gross proceeds. The units, structured as a non-public offering exempt under Section 4(a)(2) of the Securities Act, include Class A ordinary shares and warrants, creating direct equity dilution.
View raw filing on EDGAR →Nicholaos C. Krenteras and Dimitri Goulandris were appointed to the board of directors effective June 3, 2026, resulting in a three-member board. Indemnity agreements were also entered into with multiple parties in connection with the appointments.
View raw filing on EDGAR →The Board approved a bylaw amendment reducing the stockholder meeting quorum requirement from a majority (>50%) to 35% of voting power. While bylaw amendments are often routine, this particular change materially affects the governance rights and voting mechanics available to shareholders by lowering the threshold needed to conduct stockholder business. This modification could be material to investors assessing corporate governance and shareholder protections, though it does not fit neatly into the more specific event categories.
View raw filing on EDGAR →The filing discloses results of the Company's 2026 Annual Meeting of Shareholders held on June 5, 2026, with detailed voting tabulations for four proposals: election of five directors (Proposal 1), approval of bylaw amendment establishing a staggered board structure (Proposal 2), ratification of HTL International, LLC as independent auditor (Proposal 3), and adjournment authority (Proposal 4). Item 5.07 explicitly presents certified voting results from Broadridge Financial Solutions, Inc., the appointed Inspector of Elections, making this a classic shareholder_vote_results disclosure. The bylaw amendment establishing board classification is material to governance structure and investor assessment.
View raw filing on EDGAR →New Providence Acquisition Corp. III entered into material definitive agreements with co-CEOs Gary Smith and Alexander Coleman to issue $1.5 million in unsecured promissory notes with conversion rights into equity units at $10.00 per unit, creating a dilutive financing arrangement with registration rights that materially affects the registrant's capitalization structure.
View raw filing on EDGAR →BSTR Newco, LLC entered into a Business Combination Agreement with Cantor Equity Partners I, Inc. (a SPAC), involving a change of control through merger. The transaction is supported by an effective S-4 registration statement (filed June 5, 2026), private placement investments, and a proxy statement/prospectus mailed to shareholders for voting, creating direct financial obligations via convertible notes and preferred stock issuances.
View raw filing on EDGAR →Bluejay Diagnostics completed a private placement on June 5, 2026, issuing pre-funded warrants, Series G warrants, and Series H warrants to purchase up to 10,967,751 shares of common stock for approximately $7.7 million in gross proceeds to accredited investors under Section 4(a)(2) and Rule 506.
View raw filing on EDGAR →The filing discloses a material acquisition/business combination transaction in which Real Asset Acquisition Corp. (RAAQ) is combining with IQM Finland Oy, resulting in IQM becoming a publicly traded company. The core event is the announcement that the Form F-4 Registration Statement has been declared effective by the SEC on June 5, 2026, and the definitive proxy statement/prospectus has been mailed to shareholders for voting at an Extraordinary General Meeting. This represents a change of control and material M&A activity under Item 1.01/2.01 framework, even though disclosed under Item 8.01.
View raw filing on EDGAR →The filing discloses the appointment of Freddy J. Martinez to the Board of Directors as a Class III director effective June 6, 2026, filling a newly created vacancy. The disclosure emphasizes his 40+ years of experience in investment management and corporate finance with particular focus on oil and gas and cross-border transactions, directly aligned with the Company's stated strategic focus on "oil & gas opportunities in Venezuela." This is a material appointment of a qualified director to guide the Company's business combination strategy.
View raw filing on EDGAR →Ribbon Acquisition Corp. disclosed under Item 8.01 that it deposited $125,000 into its trust account to extend the deadline for completing its initial business combination by one month (from May 15, 2026 to June 15, 2026). This extension is material to shareholders because it directly affects the timeline for the SPAC's merger or acquisition activity and the risk of liquidation if no business combination is consummated by the extended deadline. While this is a routine SPAC extension mechanism, the disclosure of a specific extension payment and revised deadline is material to investors' assessment of the company's status and timeline.
View raw filing on EDGAR →FutureCorp Space Acquisition 1 consummated its IPO on June 4, 2026, raising $230 million through the sale of 23 million units and executing ancillary agreements (underwriting, warrant, trust, registration rights, and private placement agreements) in connection with the capital-raising event. As a SPAC, the IPO represents a material capital event that will fund future M&A activity.
View raw filing on EDGAR →FutureCorp Space Acquisition 1 completed a private placement of 6,000,000 warrants to the Sponsor and Representative simultaneously with IPO closing, sold at $1.00 per warrant under Section 4(a)(2) exemption. The unregistered sale of equity securities exercisable for Class A ordinary shares is material to investors assessing post-IPO capitalization and ownership structure.
View raw filing on EDGAR →Three independent directors—David J. Anderman, Shawn K. Pelsinger, and John R. Tuttle—were appointed to the Board in connection with the IPO on June 4, 2026, with assignments to key board committees (Audit, Compensation, and Nominating and Corporate Governance). This appointment establishes the governance structure and committee leadership of the newly public company.
View raw filing on EDGAR →The Amended and Restated Memorandum and Articles of Association became effective and were filed with the Cayman Islands Registrar in connection with the IPO on June 4, 2026. The transition to public company governance documents is material to investors, though the disclosure is largely procedural with full terms referenced in the Registration Statement.
View raw filing on EDGAR →The filing discloses OCC approval for a deposit acquisition by Axos Bank, a material M&A transaction previously disclosed on April 23, 2026, with expected closing later in 2026. This represents a significant corporate development affecting the registrant's asset base and business scope, meeting the materiality threshold for a reasonable investor.
View raw filing on EDGAR →aTyr Pharma received a deficiency notice on December 4, 2025, for failing to maintain a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Although the company was granted a second 180-day compliance period (until November 30, 2026) on June 3, 2026, the filing explicitly states that failure to regain compliance by that date will result in a delisting notice, with only the possibility of appeal. This is a material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the June 5, 2026 Annual Meeting of Stockholders under Item 5.07. The filing presents final voting tallies for four proposals: election of nine directors (including one designated by Apax Investor), advisory approval of executive compensation, and ratification of KPMG LLP as independent auditor. These are routine but material governance matters that affect board composition and auditor appointment.
View raw filing on EDGAR →Neurogene announced completion of dosing in its EmboldenTM registrational trial for NGN-401 in Rett syndrome treatment. This is a material clinical development milestone for a gene therapy company, as completion of a Phase 3 registrational trial dosing is a significant de-risking event that affects investor assessment of the company's pipeline and regulatory pathway. However, it does not fit neatly into the standard taxonomy categories (not earnings, M&A, litigation, impairment, or other defined event types), warranting classification as other_material.
View raw filing on EDGAR →The filing discloses a press release providing an update on a "previously announced process to evaluate strategic alternatives" for the registrant. This language suggests ongoing M&A or restructuring activity, but the Item 7.01 disclosure is vague and does not specify the nature, status, or outcome of the strategic review. Without access to the attached press release (Exhibit 99.1), the precise event type cannot be determined; however, strategic alternatives processes typically involve potential M&A, divestitures, or going-concern considerations that would be material to investors. Classified as other_material pending review of the exhibit.
View raw filing on EDGAR →Catheter Precision entered into a Securities Purchase Agreement to acquire 2,941,176 shares of Volato Group common stock for $1,000,000 in a private placement transaction. While this is technically an investment by the Company rather than an issuance of the Company's own securities, the filing is disclosed under Item 1.01 (Material Definitive Agreement) and involves a material equity transaction with significant value ($1M purchase price plus ~$1.1M in consideration received). The transaction is material to investors as it represents a substantial deployment of capital and involves equity securities with inherent valuation risk.
View raw filing on EDGAR →BioCardia sold 3,509,604 shares at $1.279 per share pursuant to an "At The Market" offering agreement with H.C. Wainwright & Co. This is a classic dilutive equity issuance under an ATM facility, which materially increases share count and dilutes existing shareholders. ATM offerings are a standard disclosure category under Item 3.02, though disclosed here under Item 8.01.
View raw filing on EDGAR →